Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolR alpha) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRa expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort